Prior to Incyte, Ms. Andrews spent 17 years at Pfizer in positions of increasing responsibility. Her last appointment was as Vice President and General Manager of the U.S. Oncology Business Unit, a $900 million portfolio of products in colorectal cancer, breast cancer and renal cell carcinoma. Ms. Andrews received her M.B.A. from the University of Michigan and a B.A. from Brown University.
BBI608 is an orally-administered first-in-class anti-cancer drug created by Boston Biomedical. It has shown the ability to inhibit the Stat3 pathways, Nanog pathways and β-catenin pathways in a pre-clinical study. BBI608 is a small-molecule compound with a novel mechanism that blocks cancer stem cells' (cancer cells with stem cell-like properties) self-renewal and induces cell death in CSC as well as other heterogeneous cancer cells. By targeting cancer stem cells in addition to heterogeneous cancer cells, efficacy is expected in the current challenges in therapy against cancer, such as treatment resistance, metastasis and recurrence. BBI608 is in a global Phase III clinical trial being conducted under a Special Protocol Assessment for metastatic colorectal cancer. Additional studies for BBI608 alone and in combination in colorectal cancer and other tumors are ongoing and planned.
About Boston Biomedical
Boston Biomedical, Inc. (Founder, President, CEO and CMO: Chiang J. Li, M.D. FACP) was founded in November, 2006 and is wholly owned by Dainippon Sumitomo Pharma Co., Ltd. Boston Biomedical Pharma Inc. (President: Hiroshi Nomura) was founded in October 2013 and is wholly owned by Dainippon Sumitomo Pharma America Holdings, I
|SOURCE Boston Biomedical|
Copyright©2012 PR Newswire.
All rights reserved